ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer

Jing Xu, Xiaolu Yang, Yunguang Li, Huang Wang, You Li, Shijie Tang, Shiwei Guo, Jiawei Zou, Xiaohan Shi, Zexi Chen, Chaoliang Zhong, Penghao Li, Wei Jing, Kailian Zheng, Xinqian Wu, Dong Gao, Luonan Chen, Gang JinbioRxiv 2025 · DOI

TL;DR

This paper introduces ODFormer, a novel computational framework that acts as a "virtual organoid" to predict how individual pancreatic cancer patients will respond to different drugs. By integrating various data types and using a sophisticated transformer architecture, ODFormer aims to overcome the cost and time barriers of traditional organoid drug testing, paving the way for more personalized and effective cancer treatments.

What Problem Does This Paper Address?

Pancreatic cancer (PC) is notoriously aggressive, making personalized treatment crucial. Patient-derived organoids (PDOs) are promising preclinical models that mimic tumor biology and predict drug responses. However, generating and testing PDOs is expensive, time-consuming, and technically complex, hindering their widespread clinical use. This creates a significant gap between promising preclinical findings and actionable clinical decisions. Existing computational models often struggle with the physiological relevance of their training data (e.g., using cell lines) and lack robust validation on real-world clinical data. The authors aim to bridge this gap by developing a computational tool that can accurately predict patient-specific drug responses using readily available data, effectively creating a "virtual organoid" for faster and more cost-effective drug screening.

Methods

ODFormer is a sophisticated computational framework built upon a transformer architecture. Its core innovation lies in a two-stage pre-training approach for its encoders:

  • Organoid Encoder: Pre-trained on a large dataset of organoid RNA-seq data to capture organoid-specific expression patterns.
  • Tissue Encoder: Pre-trained on a massive pan-cancer bulk RNA-seq dataset to learn generalizable features from diverse patient tumor tissues.

These encoders distill tissue- and organoid-specific representations, which are then integrated. The framework also incorporates:

  • Multi-modal Integration: Combines transcriptomic data, mutational profiles (using Grantham distance for encoding), and drug chemical structures (via Morgan fingerprints).
  • Transformer Architecture: Leverages self-attention mechanisms to capture complex relationships between patient omics profiles and drug features.
  • Hybrid Contrastive Loss: A novel loss function combining Adaptive Triplet Loss (to learn meaningful relationships between samples) and Distance Contrastive Loss (to align patient embeddings with drug-response relationships). This helps handle data sparsity and heterogeneity.
  • Dual-Task Prediction Heads: Allows for both continuous drug response (DR-AUC regression) and binary classification (sensitive/resistant) predictions.

Datasets

ODFormer was trained and validated on a comprehensive set of datasets:

  • Pre-training Data:
    • 30,000 pan-cancer bulk RNA-seq samples.
  • 1 million pancreatic cancer single-cell RNA-seq profiles.
  • Training & Validation Data:
    • 14,000 PDO drug-response assay measurements (DR-AUC) across 183 PDO lines and 98 therapeutic agents.
  • 191 bulk RNA-seq profiles from pancreatic cancer organoids.
  • 272 bulk RNA-seq profiles from matched primary tumor tissues.
  • Validation Cohorts:
    • Internal validation cohort (91 patients with matched PDOs and mutation profiles).
  • External validation cohort (82 patients without matched PDO data).
  • Patient-derived xenograft (PDX) models (n=39).
  • TCGA-PDAC dataset (n=68).
  • A prospective internal cohort (27 patients with matched PDOs and clinical data).
  • 16 treatment-naïve patients for prospective validation.

Key Insights and Ideas

  • Virtual Organoids are Viable: ODFormer demonstrates that a computational model can effectively mimic the predictive power of physical organoid assays, offering a scalable and cost-effective alternative.
  • Data Integration is Key: Combining transcriptomic, mutational, and drug structural data within a transformer framework unlocks more accurate and comprehensive predictions.
  • Pre-training Matters: Leveraging large-scale public datasets for pre-training significantly enhances the model's generalizability and ability to capture subtle biological patterns.
  • Novel Subtypes Emerge: By imputing missing drug response data, ODFormer identified new pancreatic cancer subtypes based on therapeutic responsiveness, not just molecular signatures, which correlated with survival outcomes.
  • Clinical Relevance is Demonstrated: The model's predictions showed significant concordance with clinical outcomes and improved patient survival when used to guide treatment decisions.

Key Results

  • High Predictive Accuracy: ODFormer achieved a Pearson Correlation Coefficient (PCC) >0.9 for standardized drug response prediction, outperforming state-of-the-art methods.
  • Drug-Level Generalization: Demonstrated superior performance in predicting responses to novel, unseen compounds.
  • Combination Therapy Prediction: Maintained strong predictive capability for drug combinations, even when trained on monotherapy data.
  • Virtual Organoid Performance: Outperformed existing methods in predicting drug responses directly from patient tumor tissue transcriptomes, achieving a 50% improvement in PCC over the second-best method for DR-AUC prediction.
  • Clinical Utility: ODFormer-guided personalized therapy selection showed significant improvement in patient outcomes.
  • Subtype Discovery: Identified four novel PC subtypes with distinct drug response profiles, validated by transcriptomic signatures and survival analysis.
  • Biomarker Identification: Identified resistance-associated genes (e.g., MUC2, SPINK4).
  • Prospective Validation: Achieved 68% accuracy in correlation with CA19-9 biomarker response in 16 treatment-naïve patients.
  • Concordance with Clinical Decisions: ODFormer recommendations showed 76% concordance with PDO-based predictions and matched physician-selected regimens in 68.75% of cases.

Limitations and Future Work

  • Data Diversity: Predictive accuracy for novel compounds or unseen patients is limited by the diversity of the training dataset. Future work will focus on expanding and diversifying the pharmacogenomic corpus.
  • Federated/Swarm Learning: To address privacy concerns with patient data and the cost of generating datasets, the authors plan to explore federated and swarm learning for decentralized model training.
  • Multi-omics Integration: While the model incorporates transcriptomic and mutational data, future work aims to integrate additional omics layers (proteomics, single-cell transcriptomics, spatial transcriptomics, histology images) to enhance predictive resolution.
  • Model Interpretability: Transformer architectures remain a frontier for interpretability, requiring dedicated efforts to improve transparency and mechanistic insight extraction.
  • Clinical Trials: While promising, definitive clinical utility will require randomized controlled trials (RCTs).
  • Broader Application: Expanding ODFormer's application beyond pancreatic cancer to other cancer types and incorporating a wider spectrum of therapeutic modalities (targeted agents, immunotherapies) is a key future direction.
  • Temporal Dynamics: Future developments may include dynamic modeling of temporal drug responses.

Summary updated

Abstract

Abstract Pancreatic cancer (PC) patient-derived organoids (PDOs) faithfully recapitulate therapeutic responses but face clinical translation barriers, including high costs and technical complexity. To address these problems and the lack of frameworks for PDO-based drug-response assays, we developed ODFormer, a computational framework that simulates PC PDOs to predict clinically actionable, patient-specific drug responses by integrating transcriptomic and mutational profiles. ODFormer first employed two encoders, pretrained on 30,000 pan-cancer bulk transcriptomics and 1 million PC single-cell profiles respectively, to distil tissue-and organoid-specific representations. Then, trained on our curated 14,000 PDO drug-response assay (across 183 PDOs and 98 drugs) using a transformer–augmented hybrid contrastive network, ODFormer significantly outperformed state-of-the-art methods, notably achieving a PCC >0.9 in predicting standardized drug response. Multi-cohort retrospective analyses further demonstrated that ODFormer-guided personalized therapy significantly improves clinical outcomes, without requiring physical organoid assays. Furthermore, ODFormer identified novel clinico-biological PC subtypes and revealed therapy resistance biomarkers by stratifying predicted responders and non-responders. These were validated using independent datasets including TCGA-PDAC. Notably, ODFormer-guided treatment efficacy showed high concordance with prospective clinical responses by CA19-9.
BibTeX
@misc{xu2025odformer,
  author = {Jing Xu and Xiaolu Yang and Yunguang Li and Huang Wang and You Li and Shijie Tang and Shiwei Guo and Jiawei Zou and Xiaohan Shi and Zexi Chen and Chaoliang Zhong and Penghao Li and Wei Jing and Kailian Zheng and Xinqian Wu and Dong Gao and Luonan Chen and Gang Jin},
  title = {{ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer}},
  year = {2025},
  doi = {10.1101/2025.07.08.663664},
  howpublished = {bioRxiv},
}
Figure